Ardelyx (ARDX) Gains from Sales and Divestitures (2016 - 2020)

Ardelyx (ARDX) reported Gains from Sales and Divestitures of $866528.0 for Q4 2020, down 3.72% quarter-over-quarter from $900000.0 in Q3 2020.

Ardelyx (ARDX) Gains from Sales and Divestitures (2016 - 2020) Analysis & Trends

Ardelyx has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $866528.0 in Q4 2020.

For the quarter ending Q4 2020, Gains from Sales and Divestitures changed N/A year-over-year to $866528.0; the trailing twelve-month figure through Dec 2020 stood at $866528.0 (changed N/A YoY), and the FY2020 full-year result was $866528.0, changed N/A from the prior year.
Gains from Sales and Divestitures for Q4 2020 stood at $866528.0, down from $900000.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $900000.0 in Q3 2020, with the low at $5000.0 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Ardelyx	1.49 Bn	1.25 Bn	89.66 Mn

Download Data